Suscribirse

Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma - 08/09/11

Doi : 10.1016/S0002-9343(99)00222-3 
Marian Korosec, MD a, R.D Novak, PhD a, Earl Myers, MD a, Mary Skowronski a : MEd, E.R McFadden, MD a, ⁎
a Division of Pulmonary and Critical Medicine and the Department of Emergency Medicine of University Hospitals and the Department of Medicine of Case Western Reserve University School of Medicine, Cleveland, Ohio, USA 

*Requests for reprints should be addressed to E. R. McFadden, Jr., MD, Division of Pulmonary and Critical Care Medicine, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, Ohio 44106–5067

Abstract

PURPOSE: The present study was undertaken to determine whether regular use of salmeterol reduces the emergency effectiveness of albuterol.

PATIENTS AND METHODS: Acutely ill asthmatic patients chronically taking salmeterol, and similar patients who were not taking salmeterol, were treated with albuterol, either as three aerosols of 2.5 mg every 20 minutes for 1 hour or two doses of 5.0 mg every 20 minutes. Peak expiratory flow measurements were monitored before and after each treatment. The time to disposition and the number of return visits were also recorded.

RESULTS: One hundred fourteen patients, 57 who took salmeterol and 57 who served as control patients, completed the study. Thirty-three patients in each group received the lower dose of albuterol, and 24 were given the larger amount. There were no significant pretreatment differences between the salmeterol and control groups in the severity of symptoms or the degree of airway obstruction. Both albuterol regimens improved peak flow. Responses in the control group and in the salmeterol group were similar (low-dose albuterol increase in peak flow = 49%, control = 35%, P = 0.37; high-dose albuterol increment in peak flow = 43%, control = 41%, P = 0.81). There were no significant differences between the control group and the salmeterol group in the mean length of stay, the proportion of subjects admitted to the hospital, or the number of return visits.

CONCLUSIONS: In patients with asthma, chronic use of salmeterol doses not interfere with the effects of standard doses of albuterol for the treatment of acute decompensations.

El texto completo de este artículo está disponible en PDF.

Esquema


 Supported in part by Specialized Center of Research (SCOR) Grant HL-37117 from the National Heart, Lung, and Blood Institute and General Clinical Research Center Grant MO-1-RR00080 from the National Center for Research Resources, National Institutes of Health, United States Public Health Service.


© 1999  Excerpta Medica Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 107 - N° 3

P. 209-213 - septembre 1999 Regresar al número
Artículo precedente Artículo precedente
  • Echocardiography in patients with suspected endocarditis: a cost-effectiveness analysis
  • Paul A Heidenreich, Frederick A Masoudi, Brijeshwar Maini, Tony M Chou, Elyse Foster, Nelson B Schiller, Douglas K Owens
| Artículo siguiente Artículo siguiente
  • Screening for colorectal cancer with flexible sigmoidoscopy by nonphysician endoscopists
  • Michael B Wallace, James Alan Kemp, Frank Meyer, Kimberly Horton, Angela Reffel, Cindy L Christiansen, Francis A Farraye

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.